UK Startup Snaps up Potential Universal Cancer Immunotherapy

The cancer vaccine developer Ervaxx has licensed a preclinical-stage ‘universal’ cancer immunotherapy based on the recent discovery of a new strain of immune T-cells at Cardiff University, UK. Last week, a team led by researchers at Cardiff University published research about T-cells capable of hunting a wide range of cancers including leukemia and melanoma. Experiments in vitro and in mice suggested that these T-cells could form the basis of a ‘universal’ cancer immunotherapy that could treat more types of cancer than current CAR-T and TCR therapies. The UK biotech Ervaxx has now closed an exclusive licensing agreement with the research group to get hold of the technology.